Infanrix hexa is prescribed during primary immunization for the prevention of hepatitis B, tetanus, diphtheria, pertussis, infection caused by hemophilic bacillus ( Pfeifer bacillus ) type b in infants (up to six weeks) and polio. The vaccine can also be given to infants who receive the first prophylactic dose from hepatitis B at birth.
The drug "Infanrix hexa" is injected deep into the lateral muscle in the upper or middle region of the thigh in the anterolateral region.
Before use, the suspension is shaken thoroughly until a homogeneous, cloudy white suspension is obtained. The lyophilized precipitate (dry) and suspension should be visually checked for changes in physical properties or the presence of any foreign particles. If changes in properties are noted or uncharacteristic particles appear, the drug should not be used. The vaccine must be disposed of.
Infanrix hexa is prepared by adding the entire suspension contained in the syringe into a container (vial) with lyophilized powder. If the kit contains a regular bottle and syringe, after transferring the suspension to powder, the mixture must be carefully and gently shaken until the lyophilisate is completely dissolved.
The finished Infanrix Hexa vaccine is drawn into the same syringe. Then the needle is removed and replaced with a new one.
If a bottle with a Bioset cap is included with the syringe, the powder becomes available after scrolling and removing the coating. The container with the suspension (syringe) is fixed by lightly pressing the Bioset. A click will indicate system activation. Turbid suspension is injected into the lyophilisate (powder). The vial must be carefully but gently shaken while holding the syringe. After complete dissolution of the precipitate, the mixture is drawn into a syringe. After this, a needle is attached to inject.
The vaccine looks more cloudy than a suspension to dissolve the powder solution. This is the norm. If any other changes are detected, the drug is not used.
The vaccine is administered immediately after preparation.
The drug is contraindicated in patients with hypersensitivity to any component or those who have recorded reactions of high sensitivity after a previous vaccination. The drug is not used if the child previously had encephalopathy of unknown etiology within a week after the last injection of vaccines containing pertussis ingredient. In such cases, the vaccination course continues to prevent tetanus, diphtheria, hemophilic bacillus, hepatitis B with an inactivated polio vaccine. The pertussis vaccination is stopped.
The following side effects are most common in medical practice after primary vaccination: hyperemia, pain, swelling, fever, irritability, drowsiness, anorexia. In extremely rare cases, an anaphylactoid reaction to drugs containing DTPa (Infanrix IPV) may occur. The use of vaccines with pertussis ingredient can cause a shock-like state or collapse and convulsions for two to three days after injection. In clinical practice, these cases have been observed extremely rarely. Moreover, all patients after such reactions recovered without complications.
When vaccinated with the Infanrix drug , reviews in most cases are positive. Indeed, parents generally do not report adverse events in children. Sometimes there is pain at the injection site. Vaccinations are generally well tolerated. The undesirable consequences that have arisen are eliminated without special difficulties. Some pediatricians admit that they have never seen children with side effects after Infanrix.